Miraval Crosses the Atlantic — and the Pacific — for Its First International Resort
Miraval's first property outside the US opens on Shura Island within Saudi Arabia's Red Sea Project. The adults-only resort — 180 rooms, 40,000 sq ft Life in Balance Spa, 39 indoor/outdoor treatment rooms — was designed by Foster + Partners and Rockwell Group. Alongside the 30-year mindfulness programming that built the brand in Arizona and Texas, the property adds Saudi-specific hammam rituals, desert-inspired therapies, and heritage experiences drawn from the region.
For advisors, this is genuinely new commissionable inventory with strong brand recognition among the high-spend wellness travel buyer. Before pitching, confirm commission structure with Hyatt (parent brand), Experience Planner availability, and any minimum-stay requirements — none have been publicly detailed at launch. The resort sits against an undeveloped coastal landscape with limited surrounding infrastructure; proactively qualify visa access and air connections for each client's nationality before quoting. First-mover advantage here is real: no other US wellness brand has comparable Red Sea presence.
GWS 2026 Names Phuket as Host and Asia-Pacific's $2 Trillion Market as Its Central Argument
The Global Wellness Summit's 20th-anniversary edition convenes at Angsana Laguna Phuket, November 10–13, anchored by the framing that Asia-Pacific's $2 trillion wellness economy — growing at 9.3% annually and now tied with Europe in scale — is the sector's new standard-setter. The summit's thesis: Asian longevity resorts integrating TCM and Ayurveda with diagnostic medicine are defining the global template.
That argument is the one advisors will need when clients ask why they should travel to Phuket instead of Zurich. Angsana Laguna is itself a bookable property and a natural add-on for advisors assembling Asia wellness itineraries in November. More commercially, GWS announcements have historically seeded the operator partnerships and program launches that reshape supply 12–18 months later; watch November coverage for 2027 pipeline signals. The $2T figure and 9.3% growth rate are now citable GWI primary-source data for client consultations.
Clients Are Arriving With Data. Properties That Use It Will Win the Rebooking.
Two streams converge on the same advisory challenge. GWI's April 2026 Aging Well report — corroborated by McKinsey data showing 70% of US and UK consumers purchased longevity-supporting products in the past year, with 60%-plus rating them 'very' or 'extremely' important — frames the industry shift explicitly as a move from aesthetics to capability and resilience. Separately, Rock Health's 8,000-person Census-matched survey finds 57% of Americans now own a health tracking device, and 59% of wearable owners already discuss that data with providers; Oura's reported IPO preparations underscore the clinical legitimacy crossing.
The combined implication is operational: clients are arriving with HRV baselines, sleep architecture histories, and CGM trend lines. Properties that actively solicit and integrate pre-arrival biometric data — Lanserhof's diagnostic intake and SHA Wellness's onboarding are current benchmarks — hold a measurable conversion and retention edge. Add to supplier due-diligence: does the program request wearable data and act on it?
GLP-1 Profits and Government R&D Dollars Are Both Flowing Into Longevity — and One Drug May Fix the Muscle-Loss Problem
Two institutional signals landed together. GLP-1 pharmaceutical profitability is being actively recycled into longevity clinic development and preventive health infrastructure, broadening the supply side advisors can book over the next several years. Simultaneously, South Korea officially committed 47.5 billion won (~$35M) to biological age reversal R&D, formally classifying aging as a treatable condition — a policy milestone that, combined with the country's existing 1M-plus annual aesthetic medical visitors and $11B export infrastructure, puts Seoul on the map for Asia longevity itineraries from 2027 onward.
On the clinical side, a peer-reviewed Nature trial (n=102) found the monoclonal antibody apitegromab preserves 54.9% more lean mass alongside tirzepatide, cutting muscle loss from 30% to 14.6% of total weight loss. The practical step for advisors today: add 'Are you on a GLP-1 medication?' to intake and route those clients toward programs with structured resistance protocols — not calorie-restriction retreats that compound muscle loss.
Gates Deploys Another $215M Into Women's Health With Menopause Named. Advisors Should Survey Suppliers Now.
Melinda French Gates' Pivotal initiative has now committed $600M to women's health, with menopause specifically named in the latest $215M tranche. The capital signals institutional confidence in a wellness travel niche that has consistently outrun available supply.
For advisors serving female clients aged 40–60, the commercial implication is near-term: funding at this scale typically accelerates protocol development and program launches within 12–18 months. The advisors who build supplier inventory in this niche before it becomes a standard client request will capture a high-spend cohort that currently has few structured options. Survey preferred partners now — SHA Wellness, Clinique La Prairie, Chiva-Som, and Kamalaya each have the infrastructure to build structured menopause programming — and ask directly what peri- and post-menopause offerings are in development for 2026–2027. Hormone-supportive longevity weeks and women-focused diagnostic retreats are the formats most likely to emerge first.